Taipei Exchange - Delayed Quote TWD

ICARES Medicus, Inc. (6612.TWO)

119.00
+2.00
+(1.71%)
As of 10:44:11 AM GMT+8. Market Open.
Loading Chart for 6612.TWO
  • Previous Close 117.00
  • Open 116.00
  • Bid 118.00 x --
  • Ask 119.50 x --
  • Day's Range 116.00 - 119.00
  • 52 Week Range 88.50 - 177.00
  • Volume 6,048
  • Avg. Volume 46,277
  • Market Cap (intraday) 5.126B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 40.07
  • EPS (TTM) 2.97
  • Earnings Date --
  • Forward Dividend & Yield 0.20 (0.17%)
  • Ex-Dividend Date Jul 8, 2024
  • 1y Target Est --

ICARES Medicus, Inc., together with its subsidiaries, engages in the design, research, development, manufacture, and sale of intraocular lenses and nanomedical devices in Taiwan, the United States, England, Japan, Spain, China, and internationally. The company offers ophthalmic medical devices, including intraocular lens for the treatment of cataract, myopia, hyperopia, presbyopia, and astigmatism; and surgical implant systems, as well as related technical services. It also provides nanomedical lubricious coatings and various surface treatments for implantable and interventional medical devices. ICARES Medicus, Inc. was incorporated in 2011 and is based in Zhubei City, Taiwan.

www.icaresmedicus.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6612.TWO

View More

Performance Overview: 6612.TWO

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6612.TWO
4.03%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
6.19%

1-Year Return

6612.TWO
2.40%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
0.27%

3-Year Return

6612.TWO
71.55%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
33.85%

5-Year Return

6612.TWO
70.22%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
99.89%

Compare To: 6612.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6612.TWO

View More

Valuation Measures

Annual
As of 5/20/2025
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    39.39

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.02

  • Price/Book (mrq)

    2.92

  • Enterprise Value/Revenue

    5.21

  • Enterprise Value/EBITDA

    16.80

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.79%

  • Return on Assets (ttm)

    3.62%

  • Return on Equity (ttm)

    4.44%

  • Revenue (ttm)

    996.44M

  • Net Income Avi to Common (ttm)

    127.4M

  • Diluted EPS (ttm)

    2.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    726.95M

  • Total Debt/Equity (mrq)

    46.49%

  • Levered Free Cash Flow (ttm)

    -206.56M

Research Analysis: 6612.TWO

View More

Company Insights: 6612.TWO

Research Reports: 6612.TWO

View More

People Also Watch